Literature DB >> 10329263

Effect of local anti-VEGF antibody treatment on tumor microvessel permeability.

H C Lichtenbeld1, N Ferarra, R K Jain, L L Munn.   

Abstract

Recent studies have shown that systemic injection of anti-VEGF antibody into tumor-bearing mice results in decreases in tumor vascular permeability, vessel diameters, and tumor regression. Using a similar animal model, we have applied anti-VEGF antibody directly to the tumor tissue growing in transparent window chambers in SCID mice. Similar to the results obtained with systemic injection, vascular permeability was greatly reduced, but the response was reached at much lower concentrations with local application. Implications of these findings on local control of tumors are discussed. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329263     DOI: 10.1006/mvre.1998.2140

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  9 in total

1.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  Matrix stiffening promotes a tumor vasculature phenotype.

Authors:  Francois Bordeleau; Brooke N Mason; Emmanuel Macklin Lollis; Michael Mazzola; Matthew R Zanotelli; Sahana Somasegar; Joseph P Califano; Christine Montague; Danielle J LaValley; John Huynh; Nuria Mencia-Trinchant; Yashira L Negrón Abril; Duane C Hassane; Lawrence J Bonassar; Jonathan T Butcher; Robert S Weiss; Cynthia A Reinhart-King
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-29       Impact factor: 11.205

Review 3.  Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.

Authors:  Dai Fukumura; Dan G Duda; Lance L Munn; Rakesh K Jain
Journal:  Microcirculation       Date:  2010-04       Impact factor: 2.628

4.  Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Authors:  Liangxian Cao; Marla Weetall; Christopher Trotta; Katherine Cintron; Jiyuan Ma; Min Jung Kim; Bansri Furia; Charles Romfo; Jason D Graci; Wencheng Li; Joshua Du; Josephine Sheedy; Jean Hedrick; Nicole Risher; Shirley Yeh; Hongyan Qi; Tamil Arasu; Seongwoo Hwang; William Lennox; Ronald Kong; Janet Petruska; Young-Choon Moon; John Babiak; Thomas W Davis; Allan Jacobson; Neil G Almstead; Art Branstrom; Joseph M Colacino; Stuart W Peltz
Journal:  Mol Cancer Ther       Date:  2018-10-23       Impact factor: 6.261

5.  Multi-modality imaging of a murine mammary window chamber for breast cancer research.

Authors:  Rachel Schafer; Hui Min Leung; Arthur F Gmitro
Journal:  Biotechniques       Date:  2014-07-01       Impact factor: 1.993

6.  Activation of Notch signaling by soluble Dll4 decreases vascular permeability via a cAMP/PKA-dependent pathway.

Authors:  Rachel Boardman; Vincent Pang; Naseeb Malhi; Amy P Lynch; Lopa Leach; Andrew V Benest; David O Bates; Maria J C Machado
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-01-25       Impact factor: 4.733

7.  Generation and characterization of an ascitogenic mesothelin-expressing tumor model.

Authors:  Wen-Fang Cheng; Chien-Fu Hung; Chee-Yin Chai; Chi-An Chen; Chien-Nan Lee; Yi-Ning Su; Wen-Yih Isaac Tseng; Chang-Yao Hsieh; Ie-Ming Shih; Tian-Li Wang; T-C Wu
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

8.  Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression.

Authors:  K A Mohammed; N Nasreen; J Hardwick; R D Van Horn; K L Sanders; V B Antony
Journal:  Lung       Date:  2003       Impact factor: 2.584

9.  Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion.

Authors:  Chenghai Sun; Rakesh K Jain; Lance L Munn
Journal:  Ann Biomed Eng       Date:  2007-09-11       Impact factor: 3.934

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.